ARCHIVES

Gramm-Rudman Cut Facing NCI Could Take $85 Million

This article is from The Cancer Letter archive.

Vol. 15 No. 40 | October 20, 1989

Download PDF Visit The Full Archive

Related Articles

FDA Committee Approves NDA for Mitxantrone

March 21, 1986

NIH-funded HapMap consortium publishes first phase of catalog.

October 28, 2005

ASCO: NCI Director Should Be A Clinician; NBCC Endorses Mary-Claire King

March 10, 1995

The NCI director and acting FDA commissioner called for faster approval of cancer drugs in speech to FDA staff.

October 21, 2005

FDA: Oncology Division Director Delap Promoted In Agency

May 29, 1998

Congress Orders Programs In Nutrition Research; Cancer Act Extension Beefs Up NCI Chief’s Authority

July 12, 1974